Literature DB >> 33479161

Association of Early-Phase In-Hospital Glycemic Fluctuation With Mortality in Adult Patients With Coronavirus Disease 2019.

Liangkai Chen1, Wenwu Sun2, Yanli Liu2, Lijuan Zhang2, Yanling Lv1, Qiang Wang1, Ding Long2, Yujun Wang2, Su Zhao3, Shuang Rong4, Li Yu5, Liegang Liu6.   

Abstract

OBJECTIVE: To investigate the association of in-hospital early-phase glycemic control with adverse outcomes among inpatients with coronavirus disease 2019 (COVID-19) in Wuhan, China. RESEARCH DESIGN AND METHODS: The study is a large case series, and data were obtained regarding consecutive patients hospitalized with COVID-19 in the Central Hospital of Wuhan between 2 January and 15 February 2020. All patients with definite outcomes (death or discharge) were included. Demographic, clinical, treatment, and laboratory information were extracted from electronic medical records. We collected daily fasting glucose data from standard morning fasting blood biochemistry to determine glycemic status and fluctuation (calculated as the square root of the variance of daily fasting glucose levels) during the 1st week of hospitalization.
RESULTS: A total of 548 patients were included in the study (median age 57 years; 298 [54%] were women, and n = 99 had diabetes [18%]), 215 suffered acute respiratory distress syndrome (ARDS), 489 survived, and 59 died. Patients who had higher mean levels of glucose during their 1st week of hospitalization were older and more likely to have a comorbidity and abnormal laboratory markers, prolonged hospital stays, increased expenses, and greater risks of severe pneumonia, ARDS, and death. Compared with patients with the lowest quartile of glycemic fluctuation, those who had the highest quartile of fluctuation magnitude had an increased risk of ARDS (risk ratio 1.97 [95% CI 1.01, 4.04]) and mortality (hazard ratio 2.73 [95% CI 1.06, 7.73]).
CONCLUSIONS: These results may have implications for optimizing glycemic control strategies in COVID-19 patients during the early phase of hospitalization.
© 2021 by the American Diabetes Association.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33479161     DOI: 10.2337/dc20-0780

Source DB:  PubMed          Journal:  Diabetes Care        ISSN: 0149-5992            Impact factor:   19.112


  10 in total

1.  Glycaemic variability is associated with all-cause mortality in COVID-19 patients with ARDS, a retrospective subcohort study.

Authors:  Bojan Hartmann; Marlo Verket; Paul Balfanz; Niels-Ulrik Hartmann; Malte Jacobsen; Julia Brandts; Michael Dreher; Nils Kossack; Dennis Häckl; Nikolaus Marx; Dirk Müller-Wieland
Journal:  Sci Rep       Date:  2022-06-14       Impact factor: 4.996

2.  Acute glycemic variability and risk of mortality in patients with sepsis: a meta-analysis.

Authors:  Xiaofei Li; Daofu Zhang; Yongxin Chen; Weiwei Ye; Shuang Wu; Lianqing Lou; Yanshuang Zhu
Journal:  Diabetol Metab Syndr       Date:  2022-04-23       Impact factor: 5.395

3.  At-admission HbA1c levels in hospitalized COVID-19 participants with and without known diabetes.

Authors:  Andrea Valle; Javier Rodriguez; Félix Camiña; Miguel A Martínez-Olmos; Juan B Ortola; Santiago Rodriguez-Segade
Journal:  Clin Chim Acta       Date:  2022-06-02       Impact factor: 6.314

4.  COVID-19 and endocrine and metabolic diseases. An updated statement from the European Society of Endocrinology.

Authors:  M Puig-Domingo; M Marazuela; B O Yildiz; A Giustina
Journal:  Endocrine       Date:  2021-05-08       Impact factor: 3.633

5.  Prognostic value of fasting hyperglycemia in patients with COVID-19 - Diagnostic test accuracy meta-analysis.

Authors:  Dewi Ratih Handayani; Henny Juliastuti; Eka Noneng Nawangsih; Yudith Yunia Kusmala; Iis Inayati Rakhmat; Arief Wibowo; Raymond Pranata
Journal:  Obes Med       Date:  2021-04-04

6.  Association Between Longitudinal Change in Abnormal Fasting Blood Glucose Levels and Outcome of COVID-19 Patients Without Previous Diagnosis of Diabetes.

Authors:  Siwei Song; Shujing Zhang; Zhihui Wang; Sufei Wang; Yanling Ma; Pei Ma; Huilin Luo; Mengyuan Wang; Yang Jin
Journal:  Front Endocrinol (Lausanne)       Date:  2021-03-30       Impact factor: 5.555

7.  Effect of linagliptin plus insulin in comparison to insulin alone on metabolic control and prognosis in hospitalized patients with SARS-CoV-2 infection.

Authors:  Rodolfo Guardado-Mendoza; Miguel Angel Garcia-Magaña; Liz Jovanna Martínez-Navarro; Hilda Elizabeth Macías-Cervantes; Rodolfo Aguilar-Guerrero; Erick L Suárez-Pérez; Alberto Aguilar-García
Journal:  Sci Rep       Date:  2022-01-11       Impact factor: 4.379

8.  Glucose control in home-isolated adults with type 1 diabetes affected by COVID-19 using continuous glucose monitoring.

Authors:  M Longo; L Scappaticcio; M Petrizzo; F Castaldo; A Sarnataro; D Forestiere; F Caiazzo; G Bellastella; M I Maiorino; A Capuano; K Esposito
Journal:  J Endocrinol Invest       Date:  2021-09-05       Impact factor: 4.256

9.  Sex-Specific Associations Between Low Muscle Mass and Glucose Fluctuations in Patients With Type 2 Diabetes Mellitus.

Authors:  Xiulin Shi; Wenjuan Liu; Lulu Zhang; Fangsen Xiao; Peiying Huang; Bing Yan; Yiping Zhang; Weijuan Su; Qiuhui Jiang; Mingzhu Lin; Wei Liu; Xuejun Li
Journal:  Front Endocrinol (Lausanne)       Date:  2022-07-13       Impact factor: 6.055

Review 10.  The three syndromes and six Chinese patent medicine study during the recovery phase of COVID-19.

Authors:  Xuedong An; Liyun Duan; Yue Hong Zhang; Shenghui Zhao; Rong Rong Zhou; Yingying Duan; Fengmei Lian; Xiaolin Tong
Journal:  Chin Med       Date:  2021-06-07       Impact factor: 5.455

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.